Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

RA Capital has led a $100m series B round for Ventus Therapeutics, which is linked to multiple universities.

The SoftBank-backed robotic technology developer has secured series B-plus funding two months after US regulators deemed its initial public offering abandoned.

GV returned to reinvest in small molecule drug developer Ventus Therapeutics having backed its $60m series A round almost a year ago.

The security automation platform developer was reportedly valued at $300m in a series B round backed by CrowdStrike's Falcon Fund.

The ride hailing and logistics service operator pulled in $15m through a series B round led by existing corporate investor Central.

RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.

Sanofi Ventures reinvested in the vaccine developer through a series B round that followed a $51m series A 18 months ago.

Google’s Gradient Ventures took part in a $35m round that increased the machine learning technology developer's total funding to $62m.